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Endothelial cells lining the vessel wall are connected by adherens, tight and gap junctions. These junctional complexes are related to those
found at epithelial junctions but with notable changes in terms of specific molecules and organization. Endothelial junctional proteins play
important roles in tissue integrity but also in vascular permeability, leukocyte extravasation and angiogenesis. In this review, we will focus on
specific mechanisms of endothelial tight and adherens junctions.
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The endothelium is located at the inner side of all vessel
types and is constituted by a monolayer of endothelial cells.
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tures, namely adherens junctions (AJ), tight junctions (TJ) and
gap junctions (GJ), playing pivotal roles in tissue integrity,
barrier function and cell–cell communication, respectively. The
endothelium constitutes the vascular barrier with regulated
permeability properties between the blood and the underlying
tissues. Quiescent endothelium may be subjected to stimuli
inducing leukocyte extravasation at inflammatory sites and
sprouting angiogenesis. Both processes have a strong impact on
endothelial cell–cell junctions. In this review, we will focus on
endothelial AJ and TJ as well as interendothelial-specific mole-
cules or mechanisms in resting and activated vessels.
1.1. Histology of endothelial junctions
The junctional structures located at the endothelial intercel-
lular cleft are related to those found in epithelia; however, their
organization is more variable and in most vascular beds their
topology is less restricted than in epithelial cells. AJ, TJ and GJ
are often intermingled and form a complex zonular system with
variations in depth and thickness of the submembrane plaque
associated with the junctional structure [1,2]. As opposed to
epithelial cells, GJs are often observed close to the luminal
surface. Therefore, the term “apical junction” used to collec-
tively designate epithelial TJ and AJ may not be applied to the
endothelium.
Another distinction comes from the difference in cell thick-
ness. With some exceptions, cell body thickness of microvas-
cular endothelium is less than 0.3 μm [2]. Overlapping strands
of adjacent endothelial cells form contact domains of 0.5–
0.9 μm. However, endothelial cell–cell contacts of some other
vessels, including arteries and high endothelial venules, may
reach 3–10 μm (Fig. 1) (deduced from [1,2]). Outside of the
electron-dense junctional structures, the intercellular cleft is
lined by parallel plasma membranes of neighbor cells separated
by 10–20 nm.
Finally, endothelial intercellular domains differ from those of
epithelial cells by the absence of desmosomes [2]. The inter-
mediate filaments, constituted in the endothelium by vimentin
molecules, are poorly linked to cell–cell contacts. However, as
opposed to the situation in epithelia, the vimentin filaments may
be linked to endothelial AJ in junctional structures similar to
desmosomes, called complexus adherens [3–8]. These struc-
tures originally described in lymphatic endothelium may have a
broader distribution in the vascular tree.Fig. 1. Electron micrograph showing an endothelial junction in mouse aorta. The
intercellular cleft (between arrowheads) is lined by two endothelial (E) strands
and extands from basal lamina to lumen (L).It must be stressed that interendothelial junctions are dyna-
mic structures, subjected to multiple regulations. Furthermore,
leukocytes extravasate at inflammatory sites (mostly in post-
capillary venules) either through transcellular or paracellular
routes. Extravasation through the intercellular junction is a rapid
and regulated process, during which the leukocyte is squeezed
in the cleft (diapedesis), followed by rapid junction reformation.
1.2. Adhesive proteins located at endothelial cell–cell contacts
A number of proteins exhibiting homophilic adhesive acti-
vities are located at interendothelial contacts (Fig. 2). Some of
them are specific to endothelial cells (e.g., VE–cadherin [9,10],
claudin-5 [11]) while others are common with epithelial cells
(e.g., occludin [12], junctional adhesionmolecule (JAM)-A [13],
nectins [14,15], claudins (see references below) and connexins
[16]), blood cells (e.g., PECAM/CD31 [17], endothelial cell-
selective adhesionmolecule (ESAM) [18,19], JAM-A, -C, CD99
(reviewed in [20])), smooth muscle cells (S-endo-1/CD146 [21])
or mesangial/trophoblast cells (protocadherin (Pcdh)12/VE–
cadherin-2 [22]). These proteins may be part of organized junc-
tional structures, such as VE–cadherin in AJ, claudins and oc-
cludin in TJ, or connexins in GJ, while others are independent,
such as PECAM, CD99, S-endo-1 or Pcdh12. The JAMs are
associated with TJ through intracellular components without
being directly involved in TJ strand formation.
Interendothelial adhesive proteins are implicated at differ-
ent levels in endothelial cell–cell interaction and tissue integ-
rity. Some of them have a dual function as they also participate
in leukocyte extravasation via homophilic (PECAM, CD99,
JAM-A, -C) or heterophilic (JAM-A, -B, -C) interactions (re-
viewed in [20]).
2. The endothelial adherens junction
2.1. The VE–cadherin-based complex and its physiological role
VE–cadherin is the transmembrane component of endothelial
AJ [23]. It is a type II cadherin harboring high adhesive activity
[24]. Several biochemical evidences showed that VE–cadherin
extracellular domains form hexamers in solution [25,26]. Elec-
tron microscopy data support this view and allowed to propose a
model in which VE–cadherin dimers interact in trans through
their extracellular domain 1 and VE–cadherin trimers interact in
cis via their extracellular domain 4 (Fig. 3) [27].
VE–cadherin intracellular domain is similar to other clas-
sical cadherins. It contains a proximal binding site for p120 and
p0071, and a distal binding site for β-catenin and plakoglobin
(Fig. 4, left). Both β-catenin and plakoglobin are linked to
α-catenin, which may further interact with α-actinin and vin-
culin (see [28] and references therein). The identity of the
molecular link for the actin filament anchorage to the cadherin–
catenin complex is still a question of debate [29]. As previously
indicated, the VE–cadherin complex may associate with the
vimentin cytoskeleton in some vascular locations [3–8]. This
association is mediated by either plakoglobin or p0071, both
interacting with desmoplakin, which in turn associates with
Fig. 3. Model of hexameric assembly of VE–cadherin extracellular domains
deduced from biochemical analyses and electron-microscopy. The model in-
cludes VE–cadherin ectodomains (EC) 1–4. Left: model with the VE–cadherin
dimers represented in violet, light-green and light-blue. Right: the fit of the
VE–cadherin model in the reconstructed hexamer. EC1 (red), EC2 (green), EC3
(cyan) and EC4 (blue) are coloured as indicated. Reproduced from [27].
Fig. 2. Adhesive proteins within the interendothelial cleft. Claudins, occluding, JAMs and ESAM are located in TJs, VE–cadherin in Ajs and connexins in gap
junctions. Nectin was detected in both Ajs and TJs, while PECAM, Pcdh12, CD99 and S-endo-1 are outside of these structures. TJs and Ajs are both linked to the actin
cytoskeleton and VE–cadherin may also be associated with vimentin filaments in some vascular beds.
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siently or permanently associates with signaling partners (see
below), and with a specific apical–basal polarity complex,
through direct interaction with PAR-3 and PAR-6 [30].
The precise mechanisms of VE–cadherin-based junction
formation remain mostly unexplored. However, Delanoë-Ayari
et al. [31] proposed a model in which VE–cadherin lateral
clustering may be achieved by membrane tension and free
VE–cadherin molecule diffusion rather than a cytoskeleton-
driven mechanism. Consistent with this hypothesis, VE–cad-
herin clusters forming artificial AJ were observed by assembly
of VE–cadherin extracellular domains at the surface of lipo-
somes [32]. As described below, the first cell–cell contacts may
be achieved by nectin interaction, which may facilitate cadherin
binding.
VE–cadherin was shown to be specifically located at junc-
tions of all endothelium subtypes [9]. VE–cadherin mRNA
were observed at the onset of vasculogenesis in the mouse
embryo [10]. Its extraendothelial expression has been observed
in case of vascular mimicry (the extravillous cytotrophoblasts
replacing the spiral artery endothelium [33] or melanoma cells
lining tumor vessels [34]), in circulating endothelial progenitors
[35] and in podocytes [36].
The VE–cadherin gene yields a single transcript and its
promoter contains functional sites for transcription factors such
Fig. 4. Adherens junctions and complexus adherens in endothelial cells. In AJs, VE–cadherin directly interacts at a membrane-distal site with α- and β-catenins and at
a juxtramembrane site with p120 and p0071. The exact molecular link between the VE–cadherin–catenin complex and the actin filaments is still obscure. The nectins
are linked to the actin cytoskeleton via afadin. In complexus adherens, VE–cadherin associates with vimentin filaments via plakoglobin/desmoplakin or p0071.
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though constitutively expressed by endothelial cells, VE–cadhe-
rin expression is enhanced by basic FGF in angiogenic situations
[41]. Furthermore, Tal, a bHLH transcription factor dramatically
upregulated during angiogenesis, activates VE–cadherin tran-
scription [40].
VE–cadherin adhesive properties are essential for optimal
homotypic cell interaction; however, the observation that VE–
cadherin-deficient embryos retained electron-dense endothelial
junctions indicates that some redundancy exist between the
several homophilic adhesive proteins located at the endothelial
surface [42]. Furthermore, VE–cadherin-deficient embryos
exhibited defective capacities in sprouting angiogenesis re-
sulting in embryonic death at midgestation, suggesting that
VE–cadherin has signaling properties required for vascular
morphogenesis. The dramatic phenotype of VE–cadherin-
deficient embryos was similar to that obtained with partial trun-
cation of VE–cadherin cytoplasmic domain [43]. This feature
further points to the implication of VE–cadherin in intracellular
signaling.
The contribution of VE–cadherin in neovessel formation has
been further demonstrated in adults by experiments using an-
tibodies directed against specific VE–cadherin epitopes, un-
masked during angiogenesis, that abrogated angiogenesis and
tumor growth in mice [44–46].
Other cadherins, namely N-cadherin [47], T-cadherin [48]
and Pcdh12 [22,49], have also been located in endothelial cells.
Albeit abundant in endothelium, N-cadherin is not or poorly
located at interendothelial junction [47]. Several converging
studies indicate that this molecule promotes heterotypic in-
teractions with perivascular cells such as pericytes [50,51].
T-cadherin has been identified in endothelium of human aorta
[48]. In vitro studies indicate that T-cadherin may participate to
various cellular processes, including migration, proliferationand survival [52–55]. Pcdh12 is located at interendothelial
junctions, mostly in angiogenic endothelium, and its function is
presently unknown [22,49].
2.2. β-catenin trafficking in endothelial cells
As described for epithelial cells, β-catenin may translocate to
the nucleus and activate several genes including cyclin D1 and
myc whose products induce entry in the cell cycle [56].
During human embryonic development, β-catenin was de-
tected in endothelial cell nuclei and cytoplasms of capillaries (in
particular in the brain), arteries and veins [57–59]. In quiescent
endothelial cells of adults, β-catenin is detectable neither in the
nucleus nor in the cytoplasm, but appears to be concentrated
at cell–cell contacts. Conversely, β-catenin is often observed
in the nucleus and cytoplasm of endothelial cells during pa-
thological angiogenesis or vascular remodeling. Consistently,
intracellular (nuclear or cytosolic, as opposed to junctional)
accumulation of β-catenin correlates with BrDU incorporation,
which therefore links the presence of intracellular β-catenin to a
proliferative state.
The conditional inactivation of β-catenin in the endothelium
leads to morphological alterations of vessels, increased vascular
permeability and eventually results in embryonic lethality at mid-
gestation [60,61]. In endothelial cells devoid of β-catenin, pla-
koglobin solely binds to VE–cadherin. As opposed to β-catenin,
plakoglobin may bind to either α-catenin or desmoplakin and
vimentin. Therefore, the VE–cadherin complex may interact
more strongly with the vimentin cytoskeleton in this context.
Altogether, these features suggest that physiological regu-
lation of endothelial junctions depends on (i) a subtle balance
between β-catenin and plakoglobin binding to VE–cadherin
and (ii) the proportion between intracellular and junctional
β-catenin.
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Besides its role in maintaining endothelium integrity, VE–
cadherin participates in the control of vascular permeability and
leukocyte transmigration, as documented by injection of VE–
cadherin function blocking antibodies in the mouse [62–64].
During leukocyte transmigration, VE–cadherin–catenin com-
plexes are pushed aside to facilitate diapedesis [65–67]. An
alternative mechanism has been described that implicates the
degradation of VE–cadherin molecules by various proteases, as
discussed below.
VEGF (vascular endothelial growth factor) is a pleiotropic
cytokine relatively specific to endothelial cells or their pro-
genitors inducing vascular permeability, cell survival or pro-
liferation in a context-dependent manner [68]. In confluent
endothelial cells, VEGF induces a rapid and transient tyrosine
phosphorylation of VE–cadherin as well as β-catenin and
plakoglobin [69]. These molecular events are accompanied by
increased paracellular permeability and decreased association of
the VE–cadherin complex with the cytoskeleton. Furthermore,
VEGFR2, the receptor transducing VEGF signals in endothe-
lial cells, interacts with the VE–cadherin complex, probably
through β-catenin [43,70]. VE–cadherin tyrosine phosphory-
lation and association to VEGFR2 was confirmed in vivo in a
model of physiological angiogenesis dependent on VEGF [71].
Src tyrosine kinase is constantly associated with VE–cadherin
[71]. Chou et al. [72] showed that Src also associates withFig. 5. VEGF-induced VE–cadherin phosphorylation and internalization via Src kina
which in turn phosphorylates VE–cadherin on Tyr-685 [71,73]. Csk may associa
proliferation in high density cell cultures [74]. Csk-VE–cadherin interaction may p
tyrosine in Src C-terminus domain. (B) Independently, VEGFwas shown to induce an
of VE–cadherin cytoplasmic domain on serine 665. Phospho-S665 VE–cadherin bec
endocytosis and degradation, and thus, junction opening [76]. More work is necessaVEGFR2 and gets activated upon VEGF stimulation. Src in-
hibitors prevent VEGF-induced VE–cadherin phosphoryla-
tion, thereby indicating that Src is an obligatory mediator in
this pathway [71]. Furthermore, Src directly phosphorylates
VE–cadherin cytoplasmic domain on tyrosine 685 (Fig. 5A)
[73]. The functional consequences of Y685 phosphorylation
remain elusive, although a direct binding of C-terminal Src
kinase (Csk) to phospho-Y685 has been reported (see below)
[74]. Other VE–cadherin tyrosine phosphorylation sites (Y658
and Y731) have been described in correlation with increased
permeability [75].
Recently, Gavard et al. [76] revealed an additional role of
VEGF in VE–cadherin endocytosis and thus junction opening
(Fig. 5B). VEGF induces the activation of the exchange factor
Vav2 via Src. Vav2 activates Rac, which in turn activates PAK
kinase, enabling phosphorylation of VE–cadherin cytoplasmic
domain on serine 665. Phospho-S665 VE–cadherin becomes a
docking site for β-arrestin-2, the binding of which triggers
VE–cadherin endocytosis.
VEGF is not the sole endothelial effector inducing tyrosine
phosphorylation of the VE–cadherin complex. Other permeabil-
ity factors, including histamine, tumor necrosis factor (TNF)-α,
platelet-activating factor (PAF) aswell as activated neutrophils or
integrin engagement phosphorylate VE–cadherin [77–83].
In quiescent vessels, VE–cadherin is in a dephosphorylated
state. Several protein tyrosine phosphatases are associated with
VE–cadherin: Dep-1 [84], VE-PTP [85], PTP-μ [86,87] andse. (A) VEGF activation induces VEGFR2 dimerization, enabling Src activation,
te with VE–cadherin phospho-tyr-685. This interaction was shown to inhibit
otentially inhibit VE–cadherin-associated Src by phosphorylating an inhibitory
activation cascade (Src→Vav2→Rac→PAK kinase) leading to phosphorylation
omes a docking site for β-arrestin-2, the binding of which triggers VE–cadherin
ry to examine the interplay between both pathways.
Fig. 6. Participation of VE–cadherin to VEGF signaling. It is clearly established
that VE–cadherin has a pivotal role in contact inhibition of cell proliferation.
VE–cadherin, through its interaction with Dep-1 or other tyrosine phosphatases
inhibits VEGF proliferation signal via MAPK activation in three ways: (i) by
reducing VEGFR2 phosphorylation, (ii) by inhibiting VEGFR2-associated Shc
phosphorylation and (iii) by decreasing VEGFR2 internalization and signaling
from endosomal compartments. VE–cadherin complex interactionwith activated
VEGFR2 also enhances VEGF survival signaling by PI3kinase/Akt pathway.
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teins, directly interact with VE–cadherin extracellular and intra-
cellular domains, respectively. Both phosphatases were shown
to dephosphorylate VE–cadherin after VEGF stimulation, lead-
ing to increased barrier function.
VE–cadherin extracellular domain is highly sensitive to pro-
teolysis and a 90-kDa related protein corresponding to its extra-
cellular domain is often detected in tissue extracts [71].
Whereas VE–cadherin cleavage by activated neutrophils has
been a question of debate, some evidences indicate that pro-
teases liberated by or at the surface of stimulated neutrophils
[89], namely neutrophil elastase and cathepsin G [90] and
probably others [91], cleave VE–cadherin, thereby facilitating
neutrophil transmigration.
VE–cadherin degradation by matrix metalloproteinase, such
as MMP-2, -7 and -9, has been documented in several settings,
including apoptosis, diabetes andDengue virus infection [92–96].
VE–cadherin is also degraded by clathrin-dependent endo-
cytosis and lysosomal targeting by a mechanism involving p120
[97–100]. P120 downregulation in endothelial cells induces a
dramatic decrease in barrier function associated with a loss of
VE–cadherin protein levels. P120 may thus be an intracellular
regulator of VE–cadherin degradation.
In conclusion, several pathways co-exist to reduce VE–cad-
herin-dependent barrier function:VE–cadherin/catenins complex
dissociation from the cytoskeleton, VE–cadherin internalization,
junctional movements and VE–cadherin degradation.
2.4. Contact inhibition of cell proliferation as a consequence of
junction formation
The essential role of VE–cadherin in contact inhibition was
revealed by two in vitro experiments. In a first study, Dejana's
group showed that proliferation was inhibited when endothe-
lial cells were seeded on dishes onto which the extracellular
VE–cadherin domain had been adsorbed [101]. More recently,
the same group reported that VE–cadherin-deficient endothe-
lial cells had lost their contact inhibition and reached increased
cell density [84].
Several signaling pathways were identified that may explain
the growth inhibition controlled by VE–cadherin.
(1) VE–cadherin might sequester β-catenin at the membrane,
thereby preventing transcriptional activation of prolifera-
tive genes. Interestingly, a study exploited this property by
ectopically expressing the VE–cadherin cytoplasmic do-
main in tumor cells to successfully block β-catenin trans-
criptional activity and specifically kill these cells [102].
(2) VE–cadherin binding to VEGFR2 leads to a dramatic
decrease in VEGFR2 tyrosine phosphorylation [84]. Con-
sequently, both MAP kinase activation and cellular pro-
liferation are reduced. The protein tyrosine phosphatase
Dep1, associated to the VE–cadherin complex, might be
responsible for VEGFR2 dephosphorylation (Fig. 6).
More recently, the mechanism by which VE–cadherin
attenuates VEGF proliferative signal has been further de-
ciphered [103]. Junctional VE–cadherin reducesVEGFR2internalization after VEGF activation and decreases re-
ceptor signaling from endosomal compartments by a
Dep1-dependent mechanism. Conversely, in sparse cells,
VEGFR2 is internalized faster and its proliferative activity
lasts longer.
(3) VE–cadherin interacts with Shc, a protein known to ac-
tivate the MAP kinase cascade, after stimulation with
VEGF [104]. This binding leads to Shc dephosphoryla-
tion probably by junctional VE–cadherin-associated
phosphatases. Phospho-Shc is able to couple Grb2-Sos
to Ras, which eventually activates the MAP kinases
(Fig. 6) [105]. Therefore, junctional docking of Shc and
its subsequent dephosphorylation may inhibit VEGF pro-
liferative activity.
(4) The protein tyrosine kinase Csk (C-terminal Src kinase) is
a negative regulator of the Src family kinases that inacti-
vates these enzymes by phosphorylation of their inhib-
itory tyrosine, thereby imposing a locked conformation
[106]. Analysis of chimeric embryos containing Csk-
deficient and wild type cells revealed defects in angio-
genic sprouting and vascular remodeling, a phenotype
reminiscent of VE–cadherin-deficient embryos [107].
Csk binds to VE–cadherin cytoplasmic domain when
Y685 is phosphorylated (Fig. 5A) [74] and Csk siRNA
inhibition in endothelial cells increases proliferation. It is
thus likely that VE–cadherin participates in cell contact
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activity.
(5) Finally, by culturing endothelial cells on patterned sub-
strates, Nelson and Chen [108] showed that VE–cadherin
may inhibit proliferation by actively decreasing cell spread-
ing. By preventing the VE–cadherin-induced change in
morphology, the authors revealed that VE–cadherin also
elicit a growth signal mediated by actin cytoskeleton
tension.
2.5. VE–cadherin implication in VEGF survival signaling and
the endothelial hemodynamic force response
Quiescent endothelial cells are resistant to harmful stimuli,
such as serum deprivation. Similar to other cadherin members,
VE–cadherin protects endothelial cells from serum deprivation-
induced apoptosis. Yet, VEGF-induced phosphorylation of PI3
kinase and subsequent activation of the serine-threonine kinase
Akt is enhanced by VE–cadherin and its binding to the VEGFR2
complex (Fig. 6) [43].
In addition, VE–cadherin induces Gas1 (growth arrest-spe-
cific 1) expression [109]. This protein efficiently protects cells
from apoptosis. Interestingly, VE–cadherin-blocking antibodies
prevent VEGF-induced stimulation of Gas1 expression, sug-
gesting that junctional assembly of VE–cadherin is required for
Gas1 induction.
Therefore, VE–cadherin acts both as a junctional sensor and
a molecular switch, directing VEGF signaling towards prolife-
ration or survival.
Endothelial cells are also exposed to and activated by the
bloodstream. Hemodynamic forces are variable along the vas-
cular tree and induce a complex response in the endothelium,
including the induction or repression of several genes as well as
modifications in cell morphology. Junction resistance to flow
stress is dependent upon VE–cadherin, and more specifically
upon its binding to plakoglobin [110]. Furthermore, loss of
VE–cadherin precludes transcriptional activation of a shear
stress-responsive promoter. In fact, VEGFR2, VE–cadherin
together with PECAM/CD31 form a mecanosensor complex
that is sufficient to activate a flow-response to heterologous
cells [111,112].
2.6. VE–cadherin and cytoskeleton organization through G
protein activation
Cadherins are good candidates as mediator of cytoskeletal
organization modifications, such as those observed during epi-
thelio-mesenchymal transition. An increasing number of studies
indicate that cadherin engagement induces activation of Rho
family GTPases.
Rac activity is associated with endothelial junction strength-
ening. Yet, its inhibition induces endothelial junction disruption
[113]. Rac may act by promoting actin polymerization or by
coupling the VE–cadherin complex to the cytoskeleton [114].
A recent study shows that acute hypoxia transiently inhibits
Rac1, leading to RhoA activation, actin stress fiber formation,
adherens junction opening and eventually increased endothelialpermeability. Conversely, re-oxygenation strongly activates Rac1
and restores the cortical location of actin filament by inhibiting
RhoA [115].
The endothelium is separated from interstitial collagens by a
basal lamina constituted by several proteins, including laminins.
Laminin I induces a sustained activation of Rac, correlated with
endothelial quiescence, while collagen I, to which sprouting
cells are exposed, triggers adherens junction disruption and
capillary morphogenesis associated with and dependent of Rho
activation [116].
Intriguingly, a recent study reports the activation of Rac1
in VEGF-treated endothelial cells, which transiently prevents
VEGF-induced paracellular permeability [117]. A dominant-
negative form of Rac1 abolishes the transient barrier effect,
whereas the established and sustained effect of VEGF is
unmodified.
Numerous reports indicate that Rac activity increases the
endothelial barrier. However, this notion was challenged by van
Wetering et al. [118], who showed that expression of con-
stitutively active Rac in endothelial cells caused a rapid and
ROS (reactive oxygen species)-dependent disruption of cell
junctions. The same group further demonstrated that activation
of Rac and subsequent production of ROS resulted in β-catenin
phosphorylation by the tyrosine kinase Pyk2 [119]. As men-
tioned above, Rac also participates in VE–cadherin internali-
zation after VEGF stimulation [76].
Altogether, these results show that Rac is involved in several
signaling pathways leading to either endothelial barrier rein-
forcement or increased permeability.
Whether it is clearly demonstrated that Rho and Rac are
potent effectors of VE–cadherin adhesive activity, the reverse
is also true. Hence, VE–cadherin re-expression in VE–cad-
herin-deficient endothelial cells increases Rac activity by aug-
menting the expression of Rac-specific guanosine-exchange
factor Tiam1 [120]. Furthermore, VE–cadherin re-expression
increases the membrane-associated pools of Tiam1, Rac and
its effector PAK (p-21 activated kinase). These properties are
lost when VE–cadherin lacks domains interacting with p120
or β-catenin.
VE–cadherin also regulates RhoA, which in turn transmits
signals via the actin cytoskeleton to adhesive proteins impli-
cated in cell-matrix attachment [108,121]. As previously men-
tioned, following cell–cell contacts, this signaling may limit
endothelial cell spreading.
Hence, VE–cadherin, by interfering with small G-protein
activity, may act on cytoskeleton organization, cell spreading
and matrix adhesion.
The GTPase Cdc42 also controls VE–cadherin activity.
Indeed, a dominant-negative mutant of Cdc42 dramatically de-
creases endothelial junction reformation following an inflam-
matory stimulation like thrombin [122]. The same group further
demonstrated that Cdc42 acts on adherens junctions by con-
trolling the binding of α-catenin to the β-catenin/VE–cadherin
complex [123]. Remarkably, the cytoplasmic domain of ex-
trajunctional VE–cadherin is capable to induce formation of
extended membrane protrusions by a Cdc42-dependent mech-
anism [124]. Hence, Cdc42 controls VE–cadherin protrusive
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merization. This mechanism, together with the potent hetero-
philic adhesion of VE–cadherin with fibrin [125], may play a
pivotal role in capillary morphogenesis.
Cyclic AMP (cAMP) is a second messenger acting down-
stream of G-protein-coupled receptors, whose production in-
creases endothelial barrier function [126]. Receptor agonists,
such as prostacyclins or prostaglandins, attenuate the hyperper-
meability induced by inflammatory stimuli [127]. A recent
study shed light on the role of Rap1, a Ras family GTPase, in
this process [128]. Elevated levels of intracellular cAMP enable
the activation of the exchange factor Epac, which is a specific
activator of Rap1. Epac or Rap1 activation decreases per-
meability by promoting the extension of VE–cadherin-based
junctions (Fig. 7) [129]. Another report indicates that the
homophilic engagement of VE–cadherin is sufficient to acti-
vate Rap1, by a mechanism dependent on the adaptor protein
MAGI-I [130]. This protein, probably recruited at the junction
by β-catenin, is associated with the exchange factor PDZ-
GEF1, which is a direct Rap1 activator (Fig. 7). Hence, first
homophilic VE–cadherin contacts may autonomously enhance
adherens junction assembly. Both the cAMP-Epac-Rap1 and
the MAGI-I-PDZ-GEF1-Rap1 pathways may interfere with
VE–cadherin-based junctions by controlling the cortical actin
cytoskeleton.Fig. 7. Rap1 activation pathways and stabilization of the endothelial barrier. Incre
activation of the exchange factor Epac, which is a specific activator of Rap1, a Ras fam
cortical actin to the VE–cadherin complex. Rap1 may also be activated by the adapto
VE–cadherin complex. These data are derived from [128–130].Although the regulation mechanisms linking AJ and the
cytoskeleton are probably not fully elucidated, it is possible to
conclude that the VE–cadherin complex is an actor of vascular
morphogenesis through actin remodeling, as well as an inte-
grator of endothelial stimuli and physiological state.
3. The endothelial tight junction
TJs show considerable variability among different segments
of the vascular tree [2]. This disparity constitutes a major
evidence of vascular bed differentiation of endothelial cells and
has a strong impact on vascular permeability and leukocyte
extravasation. Variations concern the complexity degree of the
occluding strands as well as TJ composition.
Large artery endothelial cells, which are exposed to high flow
rates, display a well-developed system of TJ. Within the micro-
vasculature, TJ are less complex in capillaries than in arterioles,
and even less in venules. As previously mentioned, post-capil-
lary venules are the primary site of leukocyte extravasation, and
accordingly, they display a high content of permeability me-
diator receptors, such as those for histamine, serotonin and
bradykinin. At the opposite, the blood–brain barrier (BBB) and
the blood retinal barrier (BRB) are particularly rich in TJ and
endothelial TJs have been mostly studied in these locations (as
reviews, see [2,28,131–135]). It is currently admitted that theased levels of intracellular cAMP by G-protein-coupled receptors enable the
ily GTPase. Rap1 activation promotes AJ extension by increasing the avidity of
r protein MAGI-I together with the exchange factor PDZ-GEF1, recruited at the
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the astrocytes through their cellular processes (end foot) and the
closely associated pericytes. Both cells produce factors, in-
cluding angiopoietin-1, TGFβ and probably other uncharacter-
ized molecules, that are required to induce the barrier phenotype
[136–138].
As discussed below, some of TJ components are specific to
endothelial cells. In addition, the same molecules might be
differentially assembled and regulated in endothelial versus
epithelial TJs. As previously mentioned, we will concentrate
herein on TJ molecules and mechanisms specific to endothelial
cells. The general organization of TJs is described in chapters
2–3 and in previous reviews [28,139]. It should be noted that
information regarding TJ component properties mostly derives
from studies on epithelial cells because of lack of convenient
endothelial cell models retaining TJ.
3.1. Claudins, occludin and the submembrane TJ complex
Claudin family members are the major TJ transmembrane
constituents, exhibiting homophilic and heterophilic (with other
claudin subtypes) adhesive activities through their extracellular
domains and forming the TJ strands [135]. As previously men-
tioned, endothelial TJs specifically and highly express claudin-
5, with a few exceptions [140]. Claudin-5-deficient mice have
selective impairment in BBB function for molecules smaller
than 800 Da [141]. This phenotype suggests a partial re-
dundancy between claudin subtypes. Yet, claudin-3 and -11
have also been characterized in endothelial cells [142–145].
Initial identification of claudin-1 and -12 [141,146] in the
endothelium is now largely questioned and was not confirmed.
Besides their barrier function, claudins also behave as specific
channels and their diversity reflects their differential function
in paracellular transport [147]. A number of pathological set-
tings associated with decreased BBB function were correlated
with lower claudin expression, thereby indicating that claudins
may be therapeutic targets in brain edema lesions [144,146,
148–152].
Another transmembrane component of TJ strands is occludin.
Although not necessary for TJ strand formation, occludin is
associated with increased TJ barrier function. In the endothe-
lium, this molecule is specifically expressed in the BBB and the
BRB [12] and its expression is increased with pericyte-derived
angiopoietin-1 [136]. Occludin downregulation has been ob-
served in various disease state associated with BBB or BRB
disruption, including stroke, diabetes as well as hypoxia/
aglycemia [153–158]. Nevertheless, the fact that genetic abla-
tion of occludin does not affect endothelial TJ organization or
permeability is intriguing andmay indicate differential functions
in man and mouse [159].
Decreased occludin contents together with increased para-
cellular permeability were observed in VEGF-treated retinal
endothelial cells. This involves a proteolytic mechanism depen-
ding on urokinase plasminogen activator (Fig. 8) [153,160].
Occludin proteolysis by metalloproteinases was also observed
after protein tyrosine phosphatase inhibition or monocyte
diapedesis [161,162]. These features suggest that occludindegradation may be one of the mechanisms increasing vascular
permeability. VEGF activation also leads to occludin phosphor-
ylation on serine/threonine residues through PKC activation in
correlation with increased permeability (Fig. 8) [163,164]. Upon
VEGF treatment, occludin is phosphorylated on multiple serine
and threonine residues, however the identification of the precise
phosphorylation sites and theirmolecular function remain elusive
[154]. Other factors, namely lysophosphatidic acid, histamine,
oxidized phospholipids, monocyte chemoattractant protein-1
(MCP-1/CCL-2) or shear-stress, induce both occludin phos-
phorylation on serine/threonine residues and increased perme-
ability (Fig. 8) [165–168]. But paradoxically, angiotensin-2 was
shown to increase blood–brain barrier function in correlation
with increased threonine phosphorylation of occludin together
with its mobilization to lipid rafts (Fig. 8) [169]. Thus, the
functional consequences of occludin phosphorylation may be
phospho-site-dependent. Stamatovic et al. [168] demonstrated
that MCP-1, in addition to occludin, also targets ZO-1, ZO-2
(see below) and claudin-5 phosphorylation on serine/threonine
residues by a signaling pathway involving Rho and PKCα.
Occludin may also be phosphorylated on tyrosine residues
following cerebral ischemia and angiotensin-2 has a negative
impact on occludin tyrosine phosphorylation level (Fig. 8)
[168,170]. In conclusion, inflammatory or angiogenic mediators
alter BBB function in part by acting on occludin integrity, loca-
lization or phosphorylation level. Conversely, hydrocortisone
treatment, through its anti-inflammatory properties, increased
occludin levels and barrier properties of retinal endothelial cells
[171].
Claudins and occludin are linked to numerous intracellular
partners, including ZO-1, -2 and -3, AF-6/afadin, PAR-3, cingu-
lin and 7H6 antigen, also present in epithelial TJs [28]. These
proteins form a molecular complex at the submembrane side of
TJs. Detailed properties of these proteins and their molecular
interactions are reviewed in other chapters and reviews [149].
Interestingly, two versions of ZO-1 resulting from alternative
splicing may be found. An 80 amino-acid domain, called α, may
be inserted in the central part of the protein.Whereas the ZO-1α+
variant is found in most epithelial cells, the ZO-1α− isoform is
only observed in endothelial cells, Sertoli cells and podocytes of
kidney glomeruli [172–174]. In general, the ZO-1α−isoform
characterizes more dynamic junctions. Symplekin, another pro-
tein located in the TJ complex of some epithelia, is absent in
endothelial cells [175].
3.2. The JAMs
JAM-A, -B, and -C constitute a family of transmembrane
adhesive proteins belonging to Ig superfamily that colocalize
with TJ, although not included in TJ strands [20]. Of note,
JAM-B localization at TJ has been challenged [176]. JAM-A
is located in epithelial and endothelial intercellular junctions
and at the surface of platelets and leukocytes [13,177], while
JAM-C expression is restricted to endothelial cells of lymphatic
sinuses and high endothelial venules of lymphatic organs, as
well as smooth muscle cells, fibroblasts and some blood cells;
however its tissue distribution varies between mouse and human
Fig. 8. Cytokines activating signaling pathways leading to occludin functional alterations (phosphorylation or proteolysis). VEGF, MCP-1, lysophosphatidic acid
(LPA) and histamine (Hist), by interaction with their cognate receptors, VEGFR2, CCR2, LPAR and HistR, respectively, induce increased occludin phosphorylation on
serine/threonine residues, in correlation with increased permeability. Signaling pathways involve PKC activity, PKCα and/or RhoA, as indicated [163,164,167,168].
VEGF also increases permeability by inducing occludin proteolysis through activation of the urokinase (uPA)/uPAR system [153,160]. Conversely, angiotensin-2
(AT2) binding to type 1 angiotensin receptor (ATR) decreases permeability by inducing threonine phosphorylation and tyrosine dephosphorylation of occludin [169].
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pressed at interendothelial junctions [180] but its tissue dis-
tribution is less documented than the two other members.
JAM-A develops homophilic adhesive activity, suggesting
that it may mediate endothelial cell–cell interaction. Its barrier
function is further demonstrated by use of blocking antibodies
or peptides [181,182]. Furthermore, the presence of JAM-A at
intercellular junctions reduces paracellular permeability [13].
Intracellularly, it interacts with several members of TJ complex
(see [183], for more details), as well as the PAR-3/aPKC/PAR-6
polarity complex, suggesting that JAM-A may be involved in
the establishment of apical–basal polarity. Most recent studies
on JAM-A are focused on its role in leukocyte transmigration.
In inflammatory conditions, JAM-A is redistributed at the apical
surface [184,185]. JAM-A, together with PECAM, CD99 [20]
and other JAMs (see below), facilitates leukocyte transmigra-
tion through the intercellular cleft. During diapedesis, JAM-A
binds heterophilically to αLβ2 integrin located on leukocytes
[186]. The phenotype of JAM-A-deficient mice confirmed its
activity in neutrophil transmigration and unveiled other func-
tions including the restriction of dendritic cell trafficking in
lymph nodes or its participation in bFGF-induced angiogenesis
[187–190].
JAM-C develops homophilic binding at interendothelial junc-
tions, where it may also interact, even with higher affinity, with
JAM-B [191,192]. As opposed to JAM-A, junctional localiza-
tion of JAM-C increases paracellular permeability, possibly bymodulating VE–cadherin cell–cell contacts [176,193]. JAM-C
promotes neutrophil transmigration via its binding to the leu-
kocyte integrin αMβ2 [192], but this activity is lost under shear-
stress conditions, suggesting a weak interaction [194]. Two
reports indicate that tumor cells also express JAM-C at their
surface [195,196]; this feature may promote the metastatic
potential of these cells by facilitating their adhesion to endo-
thelial cells via homophilic binding and their subsequent trans-
migration. JAM-C also regulates tumor cell migration by
regulating integrin activity [197]. JAM-C-deficient mice ex-
hibit growth retardation and pneumonia causing poor survival
of the mice [198]. Additionally, the number of circulating
granulocytes is increased, which seems to be caused by loss of
endothelial JAM-C as its rescue in endothelial cells is sufficient
to restore homeostasis and better survival.
ESAM is a transmembrane Ig protein related to JAMs [18].
Its expression is restricted to endothelial cell TJs and to the
surface of activated platelets. ESAMmediates homophilic bind-
ing and its only known cytoplasmic binding partner is MAGI-I
[199]. ESAM-deficient mice showed defective tumor angiogen-
esis, whereas physiological angiogenesis was normal [200].
Endothelial ESAM also participates in neutrophil extravasation
by a mechanism involving Rho activation and TJ destabilization
[201].
Collectively, these data indicate that JAM/ESAM family
members have pivotal and selective functions in leukocyte
trafficking and may also influence TJ dynamics.
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Nectins form another group of cell–cell adhesion molecules
belonging to the Ig superfamily [15,202,203]. Four members
have been described, nectin 1–4, as well as five nectin-like
molecules, Necl 1–5. Nectin C-terminus interacts with the PDZ
domain of afadin/AF-6, an actin filament-binding protein, which
connects them to the actin cytoskeleton (Fig. 4). Nectin/afadin
were found associated with TJ and AJ proteins. They participate
in the initial step of junction formation and play a fundamental
role in the establishment of polarity. The nectin-likemolecules do
not exhibit a PDZ-binding motif and do not interact with afadin.
So far, only nectin-2 and Necl-5 were identified in en-
dothelial cells [14,204]. Nectin-2 is an α-herpes receptor and
Necl-5 is the poliovirus receptor [202] and thus both receptors
may be involved in viral dissemination. Nectin-2 develops
homophilic as well as heterophilic interactions with nectin-3,
while Necl-5 does not develop homophilic binding but interacts
with nectin-3 [15]. Necl-5 is a potential receptor for DNAM-1/
CD226, a transmembrane glycoprotein expressed on a subset of
B cells and all T cells, natural killer cells, monocytes and
platelets. Necl-5 facilitates monocyte transmigration through
endothelial monolayers and may thus participate in inflamma-
tory processes in vivo. Nectin-2, which is also a DNAM-1
ligand in other cell types, does not seem to play a similar role in
endothelial cells [14].
4. Future directions
In the recent years, the number of adhesive proteins at
interendothelial junctions has stabilized and their contribution
to barrier function has been relatively well established. Never-
theless, a comprehensive view of the proteins located on the
cytoplasmic side of AJ and TJ is still missing. For example,
after years of investigation, the molecular link between the actin
cytoskeleton and the AJ remains elusive. The molecular net-
work in both junction types is probably more complex and
variable according to location and pathophysiological state than
hitherto thought. A number of endothelial adhesive proteins are
implicated in leukocyte adhesion and transmigration; their spe-
cific and sequential actions in these processes remain to be
clarified. Finally, some of these proteins have demonstrated
function in angiogenesis or cell migration through mechanisms
that need to be fully investigated.
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